source
- Inhibrx targets OX40 agonist-cancer vaccine studies from early next yearInhibrx Biosciences says its latest mid-stage results show the potential of its OX40 agonist in immunogenic cancers — but also its prospects in combination with cancer vaccines in tumors with lower…Endpoints · 1h ago↗ source
- STAT+: Inhibrx claims first win for long-sought immunotherapy target“Pushing this is like a rock up a hill, because there’s been so much failure in the space,” said Inhibrx CEO Mark Lappe.STAT · 1h ago↗ source
- Novartis reports Phase 3 pelacarsen trial fails to improve cardiovascular outcomesNovartis said its late-stage Phase 3 trial of the antisense drug pelacarsen did not show a benefit in reducing major cardiovascular events compared with placebo. The result adds to a recent string…